AnaptysBio is moving forward with a near-term divestment into two public companies – a lower cost Royal Company Retention of Gemperli and future imsidolimab royalties, and development focus Biopharma Inc Home ANB033, ANB101, rosnilimab, cash and staff.
Jumperly is an early value driver (run rate north of $1.4 billion in 2025 and growing mid-teens QoQ) and has partner Vanda’s BLA for imsidolimab PDUFA in Decemberwhich can create a second commercial franchise asset.
AnaptysBio started the year with approx 310 million dollars Cash management says that royal business needs close 20 million dollars Runway, while the biopharma side will require ~100 million dollars Funding ANB033 through Phase 2 until late 2027 or ~200 million dollars Extend to late 2028, with ANB033 readings expected by Q4 and rosnilimab showing encouraging signs of disease transformation in RA.
At AnaptysBio, Inc. Interested in? Here are five stocks we like best.
AnaptysBio (NASDAQ:ANAB) revealed plans at TD Cowen’s 46th annual healthcare conference to separate its operations into two publicly traded companies, with executives pitching the move as a way to unlock the value of a growing royalty stream while allowing the biopharma’s remaining business to focus on pipeline development.
President and CEO Daniel Faga said the company has filed Form 10 publicly and is on track to complete the separation of its biopharma operations in the next few months. According to the proposed structure, the royalty company will retain the royalty rights in GSK’s Gemperli and future royalties associated with amsidolimab, while the biopharma company will transfer ANB033 (a CD122 antagonist), ANB101 (a BDCA-2 modulator), rosnilimab, cash transfer, and employee development.
→ Defense stocks are on the rise — aerospace earnings could close the gap
Faga described the royalty business as a “virtual company” with fewer than 10 employees and less than $10 million in annual operating costs, which he said means EBIT margins in the “high 90% range.” He said the strategy was designed to return value to shareholders rather than create an acquisition franchise platform.
Faga highlighted Gemperli as the primary value driver in the specialty business, saying the drug is expected to exit run-rate revenue “north of $1.4 billion” in 2025 and grow at a “mid-teens” quarter, driven by the leading endometrial cancer. He attributed the share gains to different survival data for Keytruda and said Europe, which won approval about a year ago, may see a “significant ramp-up” as reimbursement expands.
→ IonQ in rebound mode: buy the article, respect the risk
He also pointed to upcoming data catalysts for GSK, including survival data from this year’s rectal cancer trial, and additional readings, including a Phase 2 dMMR colon cancer data set before the end of the year based on ClinicalTrials.gov, along with ongoing pivotal trials in dMMR colon cancer and head and neck cancer.
On imsidolimab, Faga said partner Wanda filed a BLA in December and now has a PDUFA date of December this year, which he said could position the royal company to end the year with a second commercial phase royal asset.
→ Supermicro: Why NVIDIA Shadow is a useful niche
AnaptysBio entered the year with $310 million in cash, Faga said. He suggested that the royalty business would require limited cash, saying that about $20 million would provide enough runway. He said the royal company is expected to be GAAP positive “out of the gate” and cash flow positive by mid-2027.
For the biopharma company, he described the financing scenarios associated with the development of ANB033:
~$100 million The cash could fund operations through mid-2027 and support ANB033 through Phase 2 trials in celiac disease and eosinophilic esophagitis (EoE), if successful.
~$200 million Could extend the runway to the back half of 2028 and support the launch of additional Phase 2 trials.
Faga said the final cash distribution is still being evaluated and is “one of the last things” to be resolved. He also noted that the company has bought back more than 11% of the stock as part of its view that there remains a “discrepancy” between the value of Gemperli’s royalty and the overall value of the company.
Regarding governance, Faga said the biopharma company’s board would be a “supermajority subset” of the current board, and he would run the biopharma business. He said the company has yet to announce the royal business board and management structure, adding that it will not require a large management team.
Faga addressed the ongoing dispute with GSK, stressing that the separation is not related to the lawsuit and that the dispute is not related to GSK’s monotherapy development of Gemperli. He said AnaptysBio’s claims relate to what it sees as breaches of contractual obligations by GSK in co-development, including exclusive obligations to develop only with Gemperli as PD-1, disclosure obligations, and an obligation to drive “best commercial returns”.
He said GSK sued in November that AnaptysBio was reneging on the contract, and that AnaptysBio later sued. He said the case is set for trial on July 14 in Delaware Chancery Court.
Regarding rosnilimab in rheumatoid arthritis (RA), Faga cited data from a phase 2b study showing statistical significance at three months, deep response at six months, and abstinence from the drug at nine months. He described it as the first drug to show disease modification in RA “in over a decade” and said the company plans to define Phase 3 parameters and costs at a Phase 2 meeting with the FDA in Q1. He reiterated that the company does not intend to commercialize RA alone and does not plan to fund a Phase 3 program using the cash earmarked for ANB033, indicating that a partnership is needed.
For ANB033, Faga explained the rationale for targeting CD122 to block IL-15 and IL-2 signaling, aiming to resolve inflammation in celiac disease by targeting intraepithelial lymphocytes and related immune pathways. He said AnaptysBio is running two celiac cohorts: a gluten challenge study designed to evaluate the prevention of damage and symptom worsening versus placebo, and a second cohort in patients with more extensive destruction treated without gluten challenge to evaluate mucosal healing through CDV-DeHptio-Dephratio. He said the company expects to report both datasets by Q4 of this year.
Faga said the gluten challenge study is a 30-patient, 1:1 randomized trial that was powered to detect a difference compared to placebo in VHCD and symptom scores. For the mucosal healing cohort, he described the readings as more exploratory, with the goal of seeing a directional or numerical improvement in VHCD at 12 weeks.
Discussing business opportunities, Faga estimated that more than 2 million people in the United States have celiac disease, about 1 million of whom are diagnosed by biopsy, and said that approximately 250,000 diagnosed patients are unresponsive to a gluten-free diet and still have celiac disease — a prime target population for treatment.
He also described EoE as a second planned indication for ANB033, citing human data from an IL-15 targeting agent showing reduced eosinophil recruitment through effects on CD8 cells, and that anti-CD122 could target CD8-driven pathways and TH2/ILC2-related inflammation. He noted that dupilumab is the only approved treatment in EoE and said that up to 30% of patients do not respond, with non-response being associated with elevated IL-15.
Finally, regarding ANB101 (BDCA-2 modulation), Faga said the company is conducting a 1A healthy volunteer study to evaluate pharmacokinetics and pharmacodynamic effects, including half-life and “long-term PD effect” related to plasmacytoid dendritic cell depletion. He cited Biogen’s ongoing Phase 3 program in systemic lupus erythematosus and cutaneous lupus, with readmissions expected later this year, and said AnaptysBio aims to position ANB101 as a differentiation candidate against an established clinical benchmark.
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio uses a proprietary somatic hypermutation platform to rapidly produce and purify human antibodies with superior efficacy and safety profiles. The company’s technology is designed to accelerate target validation and accelerate candidate selection in immune-mediated situations.
The company’s pipeline includes several clinical-stage programs targeting dermatological and inflammatory disorders.
The article “AnaptysBio details plan to split into RoyaltyCo and Biopharma at TD Cowen healthcare conference” was originally published by MarketBeat.
